Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oscar Health, Inc.OSCR · Entity 3582 | Chief Legal Officer | September 03, 2026 | September 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oscar Health, Inc.
Report date September 03, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 209,004 |
Reported balance
After 2026-09-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-03 · Sale · Disposed 9,092 · Balance 209,004 F1: The sale was effected pursuant to a Rule 10b5-1 instruction letter entered into on August 8, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of previously granted equity awards. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.97 to $31.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F3: Includes shares to be issued in connection with the vesting of one or more restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale was effected pursuant to a Rule 10b5-1 instruction letter entered into on August 8, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of previously granted equity awards.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.97 to $31.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3: Includes shares to be issued in connection with the vesting of one or more restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Signify Health, Inc.
Report date March 29, 2023 · Filed March 29, 2023
Section 16 reporting ended · disclosed 2023-03-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-03-29 transaction · row 4
3 source rows · reconciled sequenceRow 1 · 2023-03-29 · Conversion · Acquired 24,173 · Balance 154,199 F1: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock. Row 2 · 2023-03-29 · Disposition to issuer · Disposed 85,137 · Balance 69,062 F2: Pursuant to the Merger Agreement, as of the effective time of the merger (the "Effective Time"), each restricted stock unit with respect to shares of the Issuer's Class A Common Stock (each, an "Issuer RSU") that was not (i) outstanding immediately prior to the Effective Time to the extent vested and unsettled or (ii) outstanding immediately prior to the Effective Time and was held by any person who is a non-employee director, consultant or independent contractor engaged by the Issuer and was outstanding immediately prior to the Effective Time (each, a "Rollover RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable under such Rollover RSU, with respect to a number of shares of common stock of CVS Health Corporation ("CVS Health Stock") equal to the number of shares of Class A Common Stock subject to such Rollover RSU multiplied by a fraction, F3: (Continued from Footnote 2) the numerator of which is the Per Share Consideration and the denominator of which is the volume weighted average trading price (rounded to the nearest $0.01) of one share of CVS Health Stock on the New York Stock Exchange as reported on Bloomberg L.P. under the function "VWAP" (or, if not reported therein, in another authoritative source mutually selected by the parties) for the ten (10) consecutive trading days ending on (and including) the trading day that is three (3) trading days prior to the date of the closing of the Merger (the "Exchange Ratio"). Row 4 · 2023-03-29 · Disposition to issuer · Disposed 69,062 · Balance 0 F5: Pursuant to the Merger Agreement, each share of Class A Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled and converted into the right to receive the Per Share Consideration. |
| Class B Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-29 transaction · row 3
1 source rowRow 3 · 2023-03-29 · Disposition to issuer · Disposed 24,173 · Balance 0 F4: Pursuant to the Merger Agreement, each share of Class B Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled. |
| LLC Units in Cure Aggregator, LLCSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-29 · Conversion · Disposed 24,173 · Balance 0 F1: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock. |
| Employee Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.00 | Direct | 0 |
Reported balance
After 2023-03-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-29 · Disposition to issuer · Disposed 50,000 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase a share of Class A Common Stock (each, an "Issuer Option") granted by Issuer under an Issuer stock plan that was (i) outstanding as of immediately prior to the Effective Time and was vested and unexercised (but not, for the avoidance of doubt, (x) any unvested Issuer Option that was outstanding immediately prior to the Effective Time with an exercise price that is equal to or greater than $30.50 or (y) any Issuer Option that is forfeited due to failure to satisfy performance-based conditions) or (ii) outstanding immediately prior to the Effective Time and was held by a non-employee director, consultant or independent contractor of the Issuer (whether vested or unvested) (each, a "Cash-Out Option"), was cancelled and converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Per Share Consideration over the per-share exercise price of such Cash-Out Option, multiplied by F7: (Continued from Footnote 6) (2) the number of shares of Class A Common Stock then subject to such Cash-Out Option as of immediately prior to the Effective Time. F8: Pursuant to the Merger Agreement, each Issuer Option that is not a Cash-Out Option and is outstanding immediately prior to the Effective Time (each, a "Rollover Stock Option") was converted into an option to acquire, on substantially the same terms and conditions as were applicable under such Rollover Stock Option, the number of shares of CVS Health Stock (rounded down to the nearest whole share), determined by multiplying (x) the number of shares of Class A Common Stock subject to such Rollover Stock Option immediately prior to the Effective Time by (y) the Exchange Ratio, at an exercise price per share of CVS Health Stock (rounded up to the nearest whole cent) equal to (A) the exercise price per share of Class A Common Stock subject to such Rollover Stock Option divided by (B) the Exchange Ratio. |
| Employee Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.46 | Direct | 0 |
Reported balance
After 2023-03-29 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-03-29 · Disposition to issuer · Disposed 213,556 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase a share of Class A Common Stock (each, an "Issuer Option") granted by Issuer under an Issuer stock plan that was (i) outstanding as of immediately prior to the Effective Time and was vested and unexercised (but not, for the avoidance of doubt, (x) any unvested Issuer Option that was outstanding immediately prior to the Effective Time with an exercise price that is equal to or greater than $30.50 or (y) any Issuer Option that is forfeited due to failure to satisfy performance-based conditions) or (ii) outstanding immediately prior to the Effective Time and was held by a non-employee director, consultant or independent contractor of the Issuer (whether vested or unvested) (each, a "Cash-Out Option"), was cancelled and converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Per Share Consideration over the per-share exercise price of such Cash-Out Option, multiplied by F7: (Continued from Footnote 6) (2) the number of shares of Class A Common Stock then subject to such Cash-Out Option as of immediately prior to the Effective Time. |
| Employee Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.19 | Direct | 0 |
Reported balance
After 2023-03-29 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-03-29 · Disposition to issuer · Disposed 132,138 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase a share of Class A Common Stock (each, an "Issuer Option") granted by Issuer under an Issuer stock plan that was (i) outstanding as of immediately prior to the Effective Time and was vested and unexercised (but not, for the avoidance of doubt, (x) any unvested Issuer Option that was outstanding immediately prior to the Effective Time with an exercise price that is equal to or greater than $30.50 or (y) any Issuer Option that is forfeited due to failure to satisfy performance-based conditions) or (ii) outstanding immediately prior to the Effective Time and was held by a non-employee director, consultant or independent contractor of the Issuer (whether vested or unvested) (each, a "Cash-Out Option"), was cancelled and converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Per Share Consideration over the per-share exercise price of such Cash-Out Option, multiplied by F7: (Continued from Footnote 6) (2) the number of shares of Class A Common Stock then subject to such Cash-Out Option as of immediately prior to the Effective Time. F8: Pursuant to the Merger Agreement, each Issuer Option that is not a Cash-Out Option and is outstanding immediately prior to the Effective Time (each, a "Rollover Stock Option") was converted into an option to acquire, on substantially the same terms and conditions as were applicable under such Rollover Stock Option, the number of shares of CVS Health Stock (rounded down to the nearest whole share), determined by multiplying (x) the number of shares of Class A Common Stock subject to such Rollover Stock Option immediately prior to the Effective Time by (y) the Exchange Ratio, at an exercise price per share of CVS Health Stock (rounded up to the nearest whole cent) equal to (A) the exercise price per share of Class A Common Stock subject to such Rollover Stock Option divided by (B) the Exchange Ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock.
F2: Pursuant to the Merger Agreement, as of the effective time of the merger (the "Effective Time"), each restricted stock unit with respect to shares of the Issuer's Class A Common Stock (each, an "Issuer RSU") that was not (i) outstanding immediately prior to the Effective Time to the extent vested and unsettled or (ii) outstanding immediately prior to the Effective Time and was held by any person who is a non-employee director, consultant or independent contractor engaged by the Issuer and was outstanding immediately prior to the Effective Time (each, a "Rollover RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable under such Rollover RSU, with respect to a number of shares of common stock of CVS Health Corporation ("CVS Health Stock") equal to the number of shares of Class A Common Stock subject to such Rollover RSU multiplied by a fraction,
F3: (Continued from Footnote 2) the numerator of which is the Per Share Consideration and the denominator of which is the volume weighted average trading price (rounded to the nearest $0.01) of one share of CVS Health Stock on the New York Stock Exchange as reported on Bloomberg L.P. under the function "VWAP" (or, if not reported therein, in another authoritative source mutually selected by the parties) for the ten (10) consecutive trading days ending on (and including) the trading day that is three (3) trading days prior to the date of the closing of the Merger (the "Exchange Ratio").
F4: Pursuant to the Merger Agreement, each share of Class B Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled.
F5: Pursuant to the Merger Agreement, each share of Class A Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled and converted into the right to receive the Per Share Consideration.
F6: Pursuant to the Merger Agreement, each option to purchase a share of Class A Common Stock (each, an "Issuer Option") granted by Issuer under an Issuer stock plan that was (i) outstanding as of immediately prior to the Effective Time and was vested and unexercised (but not, for the avoidance of doubt, (x) any unvested Issuer Option that was outstanding immediately prior to the Effective Time with an exercise price that is equal to or greater than $30.50 or (y) any Issuer Option that is forfeited due to failure to satisfy performance-based conditions) or (ii) outstanding immediately prior to the Effective Time and was held by a non-employee director, consultant or independent contractor of the Issuer (whether vested or unvested) (each, a "Cash-Out Option"), was cancelled and converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Per Share Consideration over the per-share exercise price of such Cash-Out Option, multiplied by
F7: (Continued from Footnote 6) (2) the number of shares of Class A Common Stock then subject to such Cash-Out Option as of immediately prior to the Effective Time.
F8: Pursuant to the Merger Agreement, each Issuer Option that is not a Cash-Out Option and is outstanding immediately prior to the Effective Time (each, a "Rollover Stock Option") was converted into an option to acquire, on substantially the same terms and conditions as were applicable under such Rollover Stock Option, the number of shares of CVS Health Stock (rounded down to the nearest whole share), determined by multiplying (x) the number of shares of Class A Common Stock subject to such Rollover Stock Option immediately prior to the Effective Time by (y) the Exchange Ratio, at an exercise price per share of CVS Health Stock (rounded up to the nearest whole cent) equal to (A) the exercise price per share of Class A Common Stock subject to such Rollover Stock Option divided by (B) the Exchange Ratio.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 8, 2026 20:16 UTC | Oscar Health, Inc. OSCR · Entity 3582 | SaleClass A Common Stock | 9,092 | $31.45 | $285,943.40 |
DisclosureSEC source: 0001842979-26-000005 · wk-form4_1788898582.xml · nonDerivative · entry 1 McAnaney Adam · CIK 0001842979 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,004 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 instruction letter entered into on August 8, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of previously granted equity awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.97 to $31.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F3 · balance_after: Includes shares to be issued in connection with the vesting of one or more restricted stock units. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:16 UTC | Oscar Health, Inc. OSCR · Entity 3582 | SaleClass A Common Stock | 2,794 | $22.45 | $62,725.30 |
DisclosureSEC source: 0001842979-26-000003 · wk-form4_1780604189.xml · nonDerivative · entry 2 McAnaney Adam · CIK 0001842979 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 218,096 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 instruction letter entered into on August 8, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of previously granted equity awards. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.03 to $22.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F3 · balance_after: Includes shares to be issued in connection with the vesting of one or more restricted stock units. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:16 UTC | Oscar Health, Inc. OSCR · Entity 3582 | SaleClass A Common Stock | 7,065 | $21.74 | $153,593.10 |
DisclosureSEC source: 0001842979-26-000003 · wk-form4_1780604189.xml · nonDerivative · entry 1 McAnaney Adam · CIK 0001842979 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220,890 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 instruction letter entered into on August 8, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of previously granted equity awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.03 to $22.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F3 · balance_after: Includes shares to be issued in connection with the vesting of one or more restricted stock units. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:18 UTC | Oscar Health, Inc. OSCR · Entity 3582 | SaleClass A Common Stock | 18,710 | $13.39 | $250,526.90 |
DisclosureSEC source: 0001568651-26-000023 · wk-form4_1772659095.xml · nonDerivative · entry 2 McAnaney Adam · CIK 0001842979 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 227,955 F3 · shares: The sale was effected pursuant to a Rule 10b5-1 instruction letter entered into on August 8, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of previously granted equity awards. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:18 UTC | Oscar Health, Inc. OSCR · Entity 3582 | GrantClass A Common Stock | 67,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001568651-26-000023 · wk-form4_1772659095.xml · nonDerivative · entry 1 McAnaney Adam · CIK 0001842979 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 246,665 F1 · shares: The shares represent restricted stock units, which will vest quarterly in 12 equal installments beginning on June 1, 2026, subject to the reporting person's continuous service through each vesting date. F2 · balance_after: Includes shares to be issued in connection with the vesting of one or more restricted stock units. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:17 UTC | Oscar Health, Inc. OSCR · Entity 3582 | SaleClass A Common Stock | 1,852 | $16.59 | $30,724.68 |
DisclosureSEC source: 0001842979-25-000010 · primarydocument.xml · nonDerivative · entry 1 McAnaney Adam · CIK 0001842979 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179,241 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 instruction letter entered into on August 8, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of previously granted equity awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.37 to $16.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:16 UTC | Oscar Health, Inc. OSCR · Entity 3582 | Tax withholdingClass A Common Stock | 1,845 | $16.66 | $30,737.70 |
DisclosureSEC source: 0001842979-25-000007 · primarydocument.xml · nonDerivative · entry 1 McAnaney Adam · CIK 0001842979 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,093 F1 · shares: Reflects shares of Class A common stock withheld by the Issuer to satisfy tax withholding obligations incident to vesting of restricted stock units ("RSUs"). F2 · balance_after: Includes shares to be issued in connection with the vesting of one or more restricted stock units. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:23 UTC | Oscar Health, Inc. OSCR · Entity 3582 | Tax withholdingClass A Common Stock | 1,847 | $13.80 | $25,488.60 |
DisclosureSEC source: 0001562180-25-004439 · primarydocument.xml · nonDerivative · entry 1 McAnaney Adam · CIK 0001842979 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,938 F1 · shares: Reflects shares of Class A common stock withheld by the Issuer to satisfy tax withholding obligations incident to vesting of restricted stock units ("RSUs"). F2 · balance_after: Includes shares to be issued in connection with the vesting of one or more restricted stock units. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:48 UTC | Oscar Health, Inc. OSCR · Entity 3582 | GrantClass A Common Stock | 61,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-002211 · primarydocument.xml · nonDerivative · entry 1 McAnaney Adam · CIK 0001842979 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,785 F1 · shares: The shares represent restricted stock units, which will vest quarterly in 12 equal installments beginning on June 1, 2025, subject to the reporting person's continuous service through each vesting date. F2 · balance_after: Includes shares to be issued in connection with the vesting of one or more restricted stock units Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:21 UTC | Oscar Health, Inc. OSCR · Entity 3582 | GrantStock Options (Right to buy) · Derivative | 185,004 | $0.00 Strike: $15.27 | $0.00 |
DisclosureSEC source: 0001562180-25-001684 · primarydocument.xml · derivative · entry 2 McAnaney Adam · CIK 0001842979 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,004 Underlying: Class A Common Stock · 185,004 shares Expires 2035-02-24 F3 · derivative.exercise_date: The options will vest over four years with 25% vesting on March 1, 2026 and the remaining 75% vesting thereafter in 12 equal quarterly installments, subject to the reporting person's continuous service through each vesting date. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:21 UTC | Oscar Health, Inc. OSCR · Entity 3582 | GrantClass A Common Stock | 123,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-001684 · primarydocument.xml · nonDerivative · entry 1 McAnaney Adam · CIK 0001842979 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,376 F1 · shares: The shares represent restricted stock units, which will vest over four years with 25% vesting on March 1, 2026 and the remaining 75% vesting thereafter in 12 equal quarterly installments, subject to the reporting person's continuous service through each vesting date. F2 · balance_after: Includes shares to be issued in connection with the vesting of one or more restricted stock units Read SEC document |
| March 29, 2023 Filed Mar 29, 2023 08:55 UTC | Signify Health, Inc. SGFY · Entity 114996 | Disposition to issuerEmployee Stock Options (Right to Buy) · Derivative | 132,138 | Not disclosed Strike: $14.19 | Not disclosed |
DisclosureSEC source: 0000899243-23-009936 · doc4.xml · derivative · entry 8 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 132,138 shares Expires not disclosed F6 · price: Pursuant to the Merger Agreement, each option to purchase a share of Class A Common Stock (each, an "Issuer Option") granted by Issuer under an Issuer stock plan that was (i) outstanding as of immediately prior to the Effective Time and was vested and unexercised (but not, for the avoidance of doubt, (x) any unvested Issuer Option that was outstanding immediately prior to the Effective Time with an exercise price that is equal to or greater than $30.50 or (y) any Issuer Option that is forfeited due to failure to satisfy performance-based conditions) or (ii) outstanding immediately prior to the Effective Time and was held by a non-employee director, consultant or independent contractor of the Issuer (whether vested or unvested) (each, a "Cash-Out Option"), was cancelled and converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Per Share Consideration over the per-share exercise price of such Cash-Out Option, multiplied by F7 · price: (Continued from Footnote 6) (2) the number of shares of Class A Common Stock then subject to such Cash-Out Option as of immediately prior to the Effective Time. F8 · price: Pursuant to the Merger Agreement, each Issuer Option that is not a Cash-Out Option and is outstanding immediately prior to the Effective Time (each, a "Rollover Stock Option") was converted into an option to acquire, on substantially the same terms and conditions as were applicable under such Rollover Stock Option, the number of shares of CVS Health Stock (rounded down to the nearest whole share), determined by multiplying (x) the number of shares of Class A Common Stock subject to such Rollover Stock Option immediately prior to the Effective Time by (y) the Exchange Ratio, at an exercise price per share of CVS Health Stock (rounded up to the nearest whole cent) equal to (A) the exercise price per share of Class A Common Stock subject to such Rollover Stock Option divided by (B) the Exchange Ratio. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase a share of Class A Common Stock (each, an "Issuer Option") granted by Issuer under an Issuer stock plan that was (i) outstanding as of immediately prior to the Effective Time and was vested and unexercised (but not, for the avoidance of doubt, (x) any unvested Issuer Option that was outstanding immediately prior to the Effective Time with an exercise price that is equal to or greater than $30.50 or (y) any Issuer Option that is forfeited due to failure to satisfy performance-based conditions) or (ii) outstanding immediately prior to the Effective Time and was held by a non-employee director, consultant or independent contractor of the Issuer (whether vested or unvested) (each, a "Cash-Out Option"), was cancelled and converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Per Share Consideration over the per-share exercise price of such Cash-Out Option, multiplied by F7 · derivative.exercise_date: (Continued from Footnote 6) (2) the number of shares of Class A Common Stock then subject to such Cash-Out Option as of immediately prior to the Effective Time. F8 · derivative.exercise_date: Pursuant to the Merger Agreement, each Issuer Option that is not a Cash-Out Option and is outstanding immediately prior to the Effective Time (each, a "Rollover Stock Option") was converted into an option to acquire, on substantially the same terms and conditions as were applicable under such Rollover Stock Option, the number of shares of CVS Health Stock (rounded down to the nearest whole share), determined by multiplying (x) the number of shares of Class A Common Stock subject to such Rollover Stock Option immediately prior to the Effective Time by (y) the Exchange Ratio, at an exercise price per share of CVS Health Stock (rounded up to the nearest whole cent) equal to (A) the exercise price per share of Class A Common Stock subject to such Rollover Stock Option divided by (B) the Exchange Ratio. F6 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase a share of Class A Common Stock (each, an "Issuer Option") granted by Issuer under an Issuer stock plan that was (i) outstanding as of immediately prior to the Effective Time and was vested and unexercised (but not, for the avoidance of doubt, (x) any unvested Issuer Option that was outstanding immediately prior to the Effective Time with an exercise price that is equal to or greater than $30.50 or (y) any Issuer Option that is forfeited due to failure to satisfy performance-based conditions) or (ii) outstanding immediately prior to the Effective Time and was held by a non-employee director, consultant or independent contractor of the Issuer (whether vested or unvested) (each, a "Cash-Out Option"), was cancelled and converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Per Share Consideration over the per-share exercise price of such Cash-Out Option, multiplied by F7 · derivative.expiration_date: (Continued from Footnote 6) (2) the number of shares of Class A Common Stock then subject to such Cash-Out Option as of immediately prior to the Effective Time. F8 · derivative.expiration_date: Pursuant to the Merger Agreement, each Issuer Option that is not a Cash-Out Option and is outstanding immediately prior to the Effective Time (each, a "Rollover Stock Option") was converted into an option to acquire, on substantially the same terms and conditions as were applicable under such Rollover Stock Option, the number of shares of CVS Health Stock (rounded down to the nearest whole share), determined by multiplying (x) the number of shares of Class A Common Stock subject to such Rollover Stock Option immediately prior to the Effective Time by (y) the Exchange Ratio, at an exercise price per share of CVS Health Stock (rounded up to the nearest whole cent) equal to (A) the exercise price per share of Class A Common Stock subject to such Rollover Stock Option divided by (B) the Exchange Ratio. Read SEC document |
| March 29, 2023 Filed Mar 29, 2023 08:55 UTC | Signify Health, Inc. SGFY · Entity 114996 | Disposition to issuerEmployee Stock Options (Right to Buy) · Derivative | 213,556 | Not disclosed Strike: $8.46 | Not disclosed |
DisclosureSEC source: 0000899243-23-009936 · doc4.xml · derivative · entry 7 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 213,556 shares Expires not disclosed F6 · price: Pursuant to the Merger Agreement, each option to purchase a share of Class A Common Stock (each, an "Issuer Option") granted by Issuer under an Issuer stock plan that was (i) outstanding as of immediately prior to the Effective Time and was vested and unexercised (but not, for the avoidance of doubt, (x) any unvested Issuer Option that was outstanding immediately prior to the Effective Time with an exercise price that is equal to or greater than $30.50 or (y) any Issuer Option that is forfeited due to failure to satisfy performance-based conditions) or (ii) outstanding immediately prior to the Effective Time and was held by a non-employee director, consultant or independent contractor of the Issuer (whether vested or unvested) (each, a "Cash-Out Option"), was cancelled and converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Per Share Consideration over the per-share exercise price of such Cash-Out Option, multiplied by F7 · price: (Continued from Footnote 6) (2) the number of shares of Class A Common Stock then subject to such Cash-Out Option as of immediately prior to the Effective Time. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase a share of Class A Common Stock (each, an "Issuer Option") granted by Issuer under an Issuer stock plan that was (i) outstanding as of immediately prior to the Effective Time and was vested and unexercised (but not, for the avoidance of doubt, (x) any unvested Issuer Option that was outstanding immediately prior to the Effective Time with an exercise price that is equal to or greater than $30.50 or (y) any Issuer Option that is forfeited due to failure to satisfy performance-based conditions) or (ii) outstanding immediately prior to the Effective Time and was held by a non-employee director, consultant or independent contractor of the Issuer (whether vested or unvested) (each, a "Cash-Out Option"), was cancelled and converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Per Share Consideration over the per-share exercise price of such Cash-Out Option, multiplied by F7 · derivative.exercise_date: (Continued from Footnote 6) (2) the number of shares of Class A Common Stock then subject to such Cash-Out Option as of immediately prior to the Effective Time. F6 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase a share of Class A Common Stock (each, an "Issuer Option") granted by Issuer under an Issuer stock plan that was (i) outstanding as of immediately prior to the Effective Time and was vested and unexercised (but not, for the avoidance of doubt, (x) any unvested Issuer Option that was outstanding immediately prior to the Effective Time with an exercise price that is equal to or greater than $30.50 or (y) any Issuer Option that is forfeited due to failure to satisfy performance-based conditions) or (ii) outstanding immediately prior to the Effective Time and was held by a non-employee director, consultant or independent contractor of the Issuer (whether vested or unvested) (each, a "Cash-Out Option"), was cancelled and converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Per Share Consideration over the per-share exercise price of such Cash-Out Option, multiplied by F7 · derivative.expiration_date: (Continued from Footnote 6) (2) the number of shares of Class A Common Stock then subject to such Cash-Out Option as of immediately prior to the Effective Time. Read SEC document |
| March 29, 2023 Filed Mar 29, 2023 08:55 UTC | Signify Health, Inc. SGFY · Entity 114996 | Disposition to issuerEmployee Stock Options (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $24.00 | Not disclosed |
DisclosureSEC source: 0000899243-23-009936 · doc4.xml · derivative · entry 6 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 50,000 shares Expires not disclosed F6 · price: Pursuant to the Merger Agreement, each option to purchase a share of Class A Common Stock (each, an "Issuer Option") granted by Issuer under an Issuer stock plan that was (i) outstanding as of immediately prior to the Effective Time and was vested and unexercised (but not, for the avoidance of doubt, (x) any unvested Issuer Option that was outstanding immediately prior to the Effective Time with an exercise price that is equal to or greater than $30.50 or (y) any Issuer Option that is forfeited due to failure to satisfy performance-based conditions) or (ii) outstanding immediately prior to the Effective Time and was held by a non-employee director, consultant or independent contractor of the Issuer (whether vested or unvested) (each, a "Cash-Out Option"), was cancelled and converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Per Share Consideration over the per-share exercise price of such Cash-Out Option, multiplied by F7 · price: (Continued from Footnote 6) (2) the number of shares of Class A Common Stock then subject to such Cash-Out Option as of immediately prior to the Effective Time. F8 · price: Pursuant to the Merger Agreement, each Issuer Option that is not a Cash-Out Option and is outstanding immediately prior to the Effective Time (each, a "Rollover Stock Option") was converted into an option to acquire, on substantially the same terms and conditions as were applicable under such Rollover Stock Option, the number of shares of CVS Health Stock (rounded down to the nearest whole share), determined by multiplying (x) the number of shares of Class A Common Stock subject to such Rollover Stock Option immediately prior to the Effective Time by (y) the Exchange Ratio, at an exercise price per share of CVS Health Stock (rounded up to the nearest whole cent) equal to (A) the exercise price per share of Class A Common Stock subject to such Rollover Stock Option divided by (B) the Exchange Ratio. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase a share of Class A Common Stock (each, an "Issuer Option") granted by Issuer under an Issuer stock plan that was (i) outstanding as of immediately prior to the Effective Time and was vested and unexercised (but not, for the avoidance of doubt, (x) any unvested Issuer Option that was outstanding immediately prior to the Effective Time with an exercise price that is equal to or greater than $30.50 or (y) any Issuer Option that is forfeited due to failure to satisfy performance-based conditions) or (ii) outstanding immediately prior to the Effective Time and was held by a non-employee director, consultant or independent contractor of the Issuer (whether vested or unvested) (each, a "Cash-Out Option"), was cancelled and converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Per Share Consideration over the per-share exercise price of such Cash-Out Option, multiplied by F7 · derivative.exercise_date: (Continued from Footnote 6) (2) the number of shares of Class A Common Stock then subject to such Cash-Out Option as of immediately prior to the Effective Time. F8 · derivative.exercise_date: Pursuant to the Merger Agreement, each Issuer Option that is not a Cash-Out Option and is outstanding immediately prior to the Effective Time (each, a "Rollover Stock Option") was converted into an option to acquire, on substantially the same terms and conditions as were applicable under such Rollover Stock Option, the number of shares of CVS Health Stock (rounded down to the nearest whole share), determined by multiplying (x) the number of shares of Class A Common Stock subject to such Rollover Stock Option immediately prior to the Effective Time by (y) the Exchange Ratio, at an exercise price per share of CVS Health Stock (rounded up to the nearest whole cent) equal to (A) the exercise price per share of Class A Common Stock subject to such Rollover Stock Option divided by (B) the Exchange Ratio. F6 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase a share of Class A Common Stock (each, an "Issuer Option") granted by Issuer under an Issuer stock plan that was (i) outstanding as of immediately prior to the Effective Time and was vested and unexercised (but not, for the avoidance of doubt, (x) any unvested Issuer Option that was outstanding immediately prior to the Effective Time with an exercise price that is equal to or greater than $30.50 or (y) any Issuer Option that is forfeited due to failure to satisfy performance-based conditions) or (ii) outstanding immediately prior to the Effective Time and was held by a non-employee director, consultant or independent contractor of the Issuer (whether vested or unvested) (each, a "Cash-Out Option"), was cancelled and converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Per Share Consideration over the per-share exercise price of such Cash-Out Option, multiplied by F7 · derivative.expiration_date: (Continued from Footnote 6) (2) the number of shares of Class A Common Stock then subject to such Cash-Out Option as of immediately prior to the Effective Time. F8 · derivative.expiration_date: Pursuant to the Merger Agreement, each Issuer Option that is not a Cash-Out Option and is outstanding immediately prior to the Effective Time (each, a "Rollover Stock Option") was converted into an option to acquire, on substantially the same terms and conditions as were applicable under such Rollover Stock Option, the number of shares of CVS Health Stock (rounded down to the nearest whole share), determined by multiplying (x) the number of shares of Class A Common Stock subject to such Rollover Stock Option immediately prior to the Effective Time by (y) the Exchange Ratio, at an exercise price per share of CVS Health Stock (rounded up to the nearest whole cent) equal to (A) the exercise price per share of Class A Common Stock subject to such Rollover Stock Option divided by (B) the Exchange Ratio. Read SEC document |
| March 29, 2023 Filed Mar 29, 2023 08:55 UTC | Signify Health, Inc. SGFY · Entity 114996 | ConversionLLC Units in Cure Aggregator, LLC · Derivative | 24,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-009936 · doc4.xml · derivative · entry 5 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 24,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock. F1 · price: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock. F1 · derivative.exercise_date: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock. F1 · derivative.expiration_date: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock. Read SEC document |
| March 29, 2023 Filed Mar 29, 2023 08:55 UTC | Signify Health, Inc. SGFY · Entity 114996 | Disposition to issuerClass A Common Stock | 69,062 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-009936 · doc4.xml · nonDerivative · entry 4 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · kind: Pursuant to the Merger Agreement, each share of Class A Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled and converted into the right to receive the Per Share Consideration. F5 · price: Pursuant to the Merger Agreement, each share of Class A Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled and converted into the right to receive the Per Share Consideration. Read SEC document |
| March 29, 2023 Filed Mar 29, 2023 08:55 UTC | Signify Health, Inc. SGFY · Entity 114996 | Disposition to issuerClass B Common Stock | 24,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-009936 · doc4.xml · nonDerivative · entry 3 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · kind: Pursuant to the Merger Agreement, each share of Class B Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled. F4 · price: Pursuant to the Merger Agreement, each share of Class B Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled. Read SEC document |
| March 29, 2023 Filed Mar 29, 2023 08:55 UTC | Signify Health, Inc. SGFY · Entity 114996 | Disposition to issuerClass A Common Stock | 85,137 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-009936 · doc4.xml · nonDerivative · entry 2 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,062 F2 · kind: Pursuant to the Merger Agreement, as of the effective time of the merger (the "Effective Time"), each restricted stock unit with respect to shares of the Issuer's Class A Common Stock (each, an "Issuer RSU") that was not (i) outstanding immediately prior to the Effective Time to the extent vested and unsettled or (ii) outstanding immediately prior to the Effective Time and was held by any person who is a non-employee director, consultant or independent contractor engaged by the Issuer and was outstanding immediately prior to the Effective Time (each, a "Rollover RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable under such Rollover RSU, with respect to a number of shares of common stock of CVS Health Corporation ("CVS Health Stock") equal to the number of shares of Class A Common Stock subject to such Rollover RSU multiplied by a fraction, F3 · kind: (Continued from Footnote 2) the numerator of which is the Per Share Consideration and the denominator of which is the volume weighted average trading price (rounded to the nearest $0.01) of one share of CVS Health Stock on the New York Stock Exchange as reported on Bloomberg L.P. under the function "VWAP" (or, if not reported therein, in another authoritative source mutually selected by the parties) for the ten (10) consecutive trading days ending on (and including) the trading day that is three (3) trading days prior to the date of the closing of the Merger (the "Exchange Ratio"). F2 · price: Pursuant to the Merger Agreement, as of the effective time of the merger (the "Effective Time"), each restricted stock unit with respect to shares of the Issuer's Class A Common Stock (each, an "Issuer RSU") that was not (i) outstanding immediately prior to the Effective Time to the extent vested and unsettled or (ii) outstanding immediately prior to the Effective Time and was held by any person who is a non-employee director, consultant or independent contractor engaged by the Issuer and was outstanding immediately prior to the Effective Time (each, a "Rollover RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable under such Rollover RSU, with respect to a number of shares of common stock of CVS Health Corporation ("CVS Health Stock") equal to the number of shares of Class A Common Stock subject to such Rollover RSU multiplied by a fraction, F3 · price: (Continued from Footnote 2) the numerator of which is the Per Share Consideration and the denominator of which is the volume weighted average trading price (rounded to the nearest $0.01) of one share of CVS Health Stock on the New York Stock Exchange as reported on Bloomberg L.P. under the function "VWAP" (or, if not reported therein, in another authoritative source mutually selected by the parties) for the ten (10) consecutive trading days ending on (and including) the trading day that is three (3) trading days prior to the date of the closing of the Merger (the "Exchange Ratio"). Read SEC document |
| March 29, 2023 Filed Mar 29, 2023 08:55 UTC | Signify Health, Inc. SGFY · Entity 114996 | ConversionClass A Common Stock | 24,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-009936 · doc4.xml · nonDerivative · entry 1 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock. F1 · price: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 16:06 UTC | Signify Health, Inc. SGFY · Entity 114996 | Tax withholdingClass A Common Stock | 3,750 | $28.37 | $106,387.50 |
DisclosureSEC source: 0000950103-23-003901 · dp190408_4-mcananey.xml · nonDerivative · entry 1 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,026 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of RSUs granted on March 7, 2022. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 17:23 UTC | Signify Health, Inc. SGFY · Entity 114996 | GrantClass A Common Stock | 52,102 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-23-003477 · dp189943_4-mcananey.xml · nonDerivative · entry 1 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,776 F1 · shares: Represents a grant of restricted stock units on February 27, 2023 that will vest in equal annual installments on each of the first four anniversaries of the grant date. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 18:02 UTC | Signify Health, Inc. SGFY · Entity 114996 | GrantEmployee Stock Option (Right to Buy) · Derivative | 132,138 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0000950103-22-004329 · dp168894_4-mcananey.xml · derivative · entry 2 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,138 Underlying: Class A Common Stock · 132,138 shares Expires 2032-03-07 F2 · derivative.exercise_date: These options vest in equal annual installments on each of the first four anniversaries of the March 7, 2022 grant date. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 18:02 UTC | Signify Health, Inc. SGFY · Entity 114996 | GrantClass A Common Stock | 44,046 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-004329 · dp168894_4-mcananey.xml · nonDerivative · entry 1 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,674 F1 · shares: Represents a grant of restricted stock units on March 7, 2022 that will vest in equal annual installments on each of the first four anniversaries of the grant date. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 20:05 UTC | Signify Health, Inc. SGFY · Entity 114996 | PurchaseClass A Common Stock | 13,900 | $24.00 | $333,600.00 |
DisclosureSEC source: 0000950103-21-002449 · dp146248_4-mcananey.xml · nonDerivative · entry 3 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,628 F3 · shares: These securities were purchased through the Issuer's directed share program in connection with its initial public offering. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 20:05 UTC | Signify Health, Inc. SGFY · Entity 114996 | GrantLLC Units in Cure Aggregator, LLC · Derivative | 24,173 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-002449 · dp146248_4-mcananey.xml · derivative · entry 5 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,173 Underlying: Class A Common Stock · 24,173 shares Expires not disclosed F5 · derivative.exercise_price: The LLC Units service-vest 25% on each of the first four anniversaries of November 27, 2019 and performance-vest based on the achievement by New Mountain Capital, LLC and its affiliates of specified cash-on-cash return thresholds. Upon vesting, each LLC Unit may be converted by the holder into an LLC Unit of Cure TopCo, LLC, which may thereafter be redeemed for, together with the cancellation of a share of Class B common stock, one share of Class A common stock or a cash payment equal to the volume weighted average market price of one share of Class A common stock for each LLC Unit redeemed. The LLC Units do not expire. F2 · shares: These securities were acquired through the conversion prior to the completion of the Issuer's initial public offering of historical interests held by the reporting person in Cure Aggregator, LLC. F5 · derivative.exercise_date: The LLC Units service-vest 25% on each of the first four anniversaries of November 27, 2019 and performance-vest based on the achievement by New Mountain Capital, LLC and its affiliates of specified cash-on-cash return thresholds. Upon vesting, each LLC Unit may be converted by the holder into an LLC Unit of Cure TopCo, LLC, which may thereafter be redeemed for, together with the cancellation of a share of Class B common stock, one share of Class A common stock or a cash payment equal to the volume weighted average market price of one share of Class A common stock for each LLC Unit redeemed. The LLC Units do not expire. F5 · derivative.expiration_date: The LLC Units service-vest 25% on each of the first four anniversaries of November 27, 2019 and performance-vest based on the achievement by New Mountain Capital, LLC and its affiliates of specified cash-on-cash return thresholds. Upon vesting, each LLC Unit may be converted by the holder into an LLC Unit of Cure TopCo, LLC, which may thereafter be redeemed for, together with the cancellation of a share of Class B common stock, one share of Class A common stock or a cash payment equal to the volume weighted average market price of one share of Class A common stock for each LLC Unit redeemed. The LLC Units do not expire. F5 · derivative.underlying: The LLC Units service-vest 25% on each of the first four anniversaries of November 27, 2019 and performance-vest based on the achievement by New Mountain Capital, LLC and its affiliates of specified cash-on-cash return thresholds. Upon vesting, each LLC Unit may be converted by the holder into an LLC Unit of Cure TopCo, LLC, which may thereafter be redeemed for, together with the cancellation of a share of Class B common stock, one share of Class A common stock or a cash payment equal to the volume weighted average market price of one share of Class A common stock for each LLC Unit redeemed. The LLC Units do not expire. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 20:05 UTC | Signify Health, Inc. SGFY · Entity 114996 | GrantEmployee Stock Options (Right to Buy) · Derivative | 213,556 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0000950103-21-002449 · dp146248_4-mcananey.xml · derivative · entry 4 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,556 Underlying: Class A Common Stock · 213,556 shares Expires 2029-06-10 F1 · shares: These securities were acquired through the conversion prior to the completion of the Issuer's initial public offering of historical interests held by the reporting person in New Remedy Corp. F4 · derivative.exercise_date: The stock options service-vest in equal installments on each of June 10, 2021, 2022 and 2023 and performance-vest based on the achievement by New Mountain Capital, LLC and its affiliates of specified multiple of invested capital return thresholds. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 20:05 UTC | Signify Health, Inc. SGFY · Entity 114996 | GrantClass B Common Stock | 24,173 | $0.01 | $241.73 |
DisclosureSEC source: 0000950103-21-002449 · dp146248_4-mcananey.xml · nonDerivative · entry 2 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,173 F2 · shares: These securities were acquired through the conversion prior to the completion of the Issuer's initial public offering of historical interests held by the reporting person in Cure Aggregator, LLC. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 20:05 UTC | Signify Health, Inc. SGFY · Entity 114996 | GrantClass A Common Stock | 23,728 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-002449 · dp146248_4-mcananey.xml · nonDerivative · entry 1 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,728 F1 · shares: These securities were acquired through the conversion prior to the completion of the Issuer's initial public offering of historical interests held by the reporting person in New Remedy Corp. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 16:50 UTC | Signify Health, Inc. SGFY · Entity 114996 | GrantEmployee Stock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0000950103-21-002273 · dp145999_4-mcananey.xml · derivative · entry 1 McAnaney Adam · CIK 0001842979 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Stock · 50,000 shares Expires 2031-02-10 F1 · derivative.exercise_date: The options vest in equal annual installments on each of the first three anniversaries of the February 10, 2021 grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.